Opus Genetics, Stock Probability of Future Stock Price Finishing Under 0.99
| IRD Stock | 0.98 0.01 1.01% |
Opus |
Opus Genetics, Target Price Odds to finish below 0.99
The tendency of Opus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under 0.99 after 90 days |
| 0.98 | 90 days | 0.99 | about 8.69 |
Based on a normal probability distribution, the odds of Opus Genetics, to stay under 0.99 after 90 days from now is about 8.69 (This Opus Genetics, probability density function shows the probability of Opus Stock to fall within a particular range of prices over 90 days) . Probability of Opus Genetics, price to stay between its current price of 0.98 and 0.99 at the end of the 90-day period is about 1.08 .
Considering the 90-day investment horizon the stock has the beta coefficient of 2.45 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Opus Genetics, will likely underperform. Additionally Opus Genetics, has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Opus Genetics, Price Density |
| Price |
Predictive Modules for Opus Genetics,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Opus Genetics,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Opus Genetics, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Opus Genetics, is not an exception. The market had few large corrections towards the Opus Genetics,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Opus Genetics,, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Opus Genetics, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.52 | |
β | Beta against Dow Jones | 2.45 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | -0.09 |
Opus Genetics, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Opus Genetics, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Opus Genetics, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Opus Genetics, generated a negative expected return over the last 90 days | |
| Opus Genetics, has high historical volatility and very poor performance | |
| Opus Genetics, has some characteristics of a very speculative penny stock | |
| Opus Genetics, has high likelihood to experience some financial distress in the next 2 years | |
| Opus Genetics, was previously known as Ocuphire Pharma and was traded on NASDAQ Exchange under the symbol OCUP. | |
| The company reported the last year's revenue of 19.05 M. Reported Net Loss for the year was (9.99 M) with profit before taxes, overhead, and interest of 0. | |
| Opus Genetics, generates negative cash flow from operations | |
| Opus Genetics, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy |
Opus Genetics, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Opus Stock often depends not only on the future outlook of the current and potential Opus Genetics,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Opus Genetics,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 24 M |
Opus Genetics, Technical Analysis
Opus Genetics,'s future price can be derived by breaking down and analyzing its technical indicators over time. Opus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Opus Genetics,. In general, you should focus on analyzing Opus Stock price patterns and their correlations with different microeconomic environments and drivers.
Opus Genetics, Predictive Forecast Models
Opus Genetics,'s time-series forecasting models is one of many Opus Genetics,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Opus Genetics,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Opus Genetics,
Checking the ongoing alerts about Opus Genetics, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Opus Genetics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Opus Genetics, generated a negative expected return over the last 90 days | |
| Opus Genetics, has high historical volatility and very poor performance | |
| Opus Genetics, has some characteristics of a very speculative penny stock | |
| Opus Genetics, has high likelihood to experience some financial distress in the next 2 years | |
| Opus Genetics, was previously known as Ocuphire Pharma and was traded on NASDAQ Exchange under the symbol OCUP. | |
| The company reported the last year's revenue of 19.05 M. Reported Net Loss for the year was (9.99 M) with profit before taxes, overhead, and interest of 0. | |
| Opus Genetics, generates negative cash flow from operations | |
| Opus Genetics, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy |
Check out Opus Genetics, Backtesting, Opus Genetics, Valuation, Opus Genetics, Correlation, Opus Genetics, Hype Analysis, Opus Genetics, Volatility, Opus Genetics, History as well as Opus Genetics, Performance. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.